For the treatment of emesis in cancer patients receiving highly emetogenic chemotherapy.

For patients receiving intravenous chemotherapy or radiation therapy who have not experienced adequate control with other available anti-emetics.

For patients receiving intravenous chemotherapy or radiation therapy who experience intolerable side effects with other anti- emetics.

For the treatment of emesis in patients receiving radiation therapy which consists of single fraction treatment to the abdominal cavity, hemi-body irradiation and total body irradiation. The therapeutic value of GRANISETRON HCL more than 24 hours after the last dose of chemotherapy is unproven.

For the treatment of emesis in cancer patients receiving moderately emetogenic chemotherapy (MEC) regimens.